Skip to main content
Zhejiang Haisen Pharmaceutical Co., Ltd. logo

Zhejiang Haisen Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 001367 ISIN · CNE1000061L9 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 386 across all filing types
Latest filing 2026-04-27 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 001367

About Zhejiang Haisen Pharmaceutical Co., Ltd.

https://www.haisenpharma.com

Zhejiang Haisen Pharmaceutical Co., Ltd. specializes in the research, development, production, and sale of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The company's core product portfolio includes a wide range of chemical raw materials, with a significant focus on antipyretic and analgesic drugs, such as Metamizole Sodium (Analgin). Additionally, the firm produces gastrointestinal agents like Sucralfate and various cardiovascular and antibiotic intermediates. Operating with advanced manufacturing facilities that adhere to international quality standards, including GMP certifications, the company serves a global market across Asia, Europe, and the Americas. Its competitive advantage lies in large-scale production capabilities, integrated R&D processes, and a commitment to stringent quality control, positioning it as a key supplier in the global pharmaceutical supply chain.

Recent filings

Filing Released Lang Actions
北京德恒（杭州）律师事务所关于浙江海森药业股份有限公司2025年年度股东会的法律意见
AGM Information Classification · 95% confidence The document is a legal opinion issued by a law firm regarding the legality of the convening, procedures, attendance, and voting results of the 2025 Annual General Meeting (AGM) of Zhejiang Haisen Pharmaceutical Co., Ltd. It details the meeting notice, attendance, voting procedures, and results for various agenda items including approval of the annual report, profit distribution, auditor appointment, and remuneration plans. The document is not the AGM materials or minutes themselves but a legal opinion on the AGM's compliance and validity. This fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM or related official documents about the AGM. The document is over 5,000 characters and contains substantive content about the AGM's legality and voting results, not just an announcement or certification. Therefore, the correct classification is AGM Information (AGM-R).
2026-04-27 Chinese
关于财务负责人退休离任暨聘任财务负责人的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the retirement and appointment of the company's financial officer. It details the resignation of the previous financial officer due to retirement and the appointment of a new financial officer, including their qualifications and compliance with relevant laws and regulations. There is no financial data, report, or presentation included. This fits the category of Board/Management Information (MANG), which covers announcements of changes in senior management.
2026-04-27 Chinese
2026年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '浙江海森药业股份有限公司2026年第一季度报告' which translates to 'Zhejiang Haisen Pharmaceutical Co., Ltd. 2026 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and explanations of financial metrics for the first quarter of 2026. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. It also mentions that the report is unaudited. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2026
2026-04-27 Chinese
2025年年度股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2025年年度股东会决议公告" which translates to "2025 Annual General Meeting Resolution Announcement." It details the convening and attendance of the shareholders' meeting, voting results on various proposals including the annual report, board work report, profit distribution, auditor appointment, and remuneration plans. The document includes voting percentages and legal opinions confirming the validity of the meeting and resolutions. The content is focused on the announcement of the voting results from the Annual General Meeting rather than the full annual report or other detailed financial disclosures. The document length is 3463 characters, which is relatively short and consistent with a voting results announcement rather than a full report. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-04-27 Chinese
第三届董事会第二十次会议决议
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 20th meeting of the third board of directors of Zhejiang Haisen Pharmaceutical Co., Ltd. It includes details about the meeting's convening, attendance, and voting results on various board matters such as the election of a new chairman, appointment of a financial officer, and approval of the first quarter report. The document does not contain the actual financial report or detailed financial data but references other announcements where the financial report and related information are published. The focus is on board decisions and management changes rather than the financial report itself. Therefore, this document fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2026-04-27 Chinese
关于持股5%以上股东减持股份的预披露公告
Major Shareholding Notification Classification · 100% confidence The document is a detailed announcement regarding a planned reduction of shareholding by a shareholder holding more than 5% of the company's shares. It includes specifics about the shareholder, the number and percentage of shares to be reduced, the methods of reduction, the timing, legal compliance, and risk disclosures. The document is not a financial report, earnings release, or management discussion, but rather a formal disclosure about a significant shareholder's intention to reduce their stake. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. The document length is 3743 characters, which is sufficient for a full announcement rather than a brief notice or a report publication announcement. Therefore, the correct classification is MRQ.
2026-04-19 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.